| Title |
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial
|
|---|---|
| Published in |
Trials, June 2020
|
| DOI | 10.1186/s13063-020-04447-3 |
| Pubmed ID | |
| Authors |
Jonathan Rilinger, Winfried V. Kern, Daniel Duerschmied, Alexander Supady, Christoph Bode, Dawid L. Staudacher, Tobias Wengenmayer |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 410 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 410 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 49 | 12% |
| Student > Master | 43 | 10% |
| Researcher | 40 | 10% |
| Other | 30 | 7% |
| Student > Ph. D. Student | 24 | 6% |
| Other | 80 | 20% |
| Unknown | 144 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 130 | 32% |
| Nursing and Health Professions | 32 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 5% |
| Biochemistry, Genetics and Molecular Biology | 11 | 3% |
| Social Sciences | 9 | 2% |
| Other | 58 | 14% |
| Unknown | 148 | 36% |